Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isosorbide mononitrate + amlodipine
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination drug consisting of isosorbide mononitrate (a nitrate vasodilator) and amlodipine (a calcium channel blocker). This combination is used primarily for treating patients with ischemic heart disease and arterial hypertension. Isosorbide mononitrate works by releasing nitric oxide, which relaxes vascular smooth muscle, predominantly affecting veins. Amlodipine blocks calcium entry into smooth muscle cells, relaxing and widening blood vessels. Together, they provide enhanced vasodilation effects, improved blood pressure control, increased exercise tolerance, and better angina relief than either drug alone.
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)sGC (Soluble Guanylyl Cyclase)NO2- (Nitrite)
Beyond the preview
Go deeper on isosorbide mononitrate + amlodipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isosorbide mononitrate + amlodipine.